Vaccine halts cancer relapse in trial

A trial has shown that a personalized vaccine, developed by Merck and Moderna, combined with an existing immunotherapy drug, can prevent skin cancer from returning in high-risk melanoma patients. The phase three study involved over 1,000 patients and indicated that the combined treatment increased the time patients remained cancer-free. Experts caution that full results are pending review, and the vaccine still requires regulatory approval before broader use.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل